2-Methyltryptamine CAS 2731-06-8 Puritas >99.0% (HPLC)

Description:

Nomen chemicum: 2-Methyltryptamine

CAS: 2731-06-8

Puritas: >99.0% (HPLC)

Aspectus: Brown solidus

Medium Panobinostat (CAS: 404950-80-7)

High Quality, Commercial Production

E-Mail: alvin@ruifuchem.com

Mitte ad nos inscriptio

Product Detail

Product Tags

Descriptio:

Manufacturer Supple Quality, Commercial Productio
Nomen chemicum: 2-Methyltryptamine CAS: 2731-06-8

Chemical Properties:

Nomen chemicum	2-Methyltryptamine
Synonyma	2-Methylindole-3-Ethylamine;2-(2-Methyl-1H-indol-3-yl)ethanamine;3-(2-Aminoethyl) -2-Methylindole
CAS Number	2731-06-8
CATTUS Number	RF-PI1480
Stock Status	In Stock, Productio Ascendite ad Tons
Formulae hypotheticae	C11H14N2
M. Pondus	174.25
Liquescens punctum	106.0 ad 110.0℃
Ferveret	177℃/1.5mmHg(lit.)
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Aspectus	Firmus Brown
Puritas / Analysis Methodus	>99.0% (HPLC Area)
1-HNMR	Congruunt cum Structure
Damnum in Siccatio	<1.00%
una immunditia	<0.50%
Totalis immunditias	<1.00%
Metalla gravia (ut Pb)	<20ppm
Test Standard	Enterprise Standard
Consuetudinem	Pharmaceutical Intermedia;Panobinostat Intermedia

Sarcina & Repono:

sarcina: Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris.

Repono Condition:Repone in vasis signatis in loco frigido et sicco;A luce et humore protege.

commoda:

FAQ:

Applicatio:

2-Methyltryptamine (CAS: 2731-06-8) clavis est materia prima in synthesi Panobinostat (LBH589) (CAS: 404950-80-7).Panobinostat potens inhibitor omnium histonum deacetylasium (HDACs), cum valore Ki vndique ab 0.6 ad 31 nM pro HDAC1-11.Per hanc actionem ad acetylationem e servo celluloso, inde in cycli cycli prehendi et apoptosin in cellulis cancri ducit.Panobinostat primus HDAC inhibitor probatus est a FDA ad tractationem myeloma multiplex.Panobinostat ut Farydak venale est, in compositione cum Bortezomib (CAS: 179324-69-7) et Dexamethasone (CAS: 50-02-2) relapsus est ut multiplex myeloma tractaret post praevia curationem cum Bortezomib et immunomodulatore.